Vasculitic Neuropathy Medication
- Author: Abbas Mehdi, MD; Chief Editor: Nicholas Lorenzo, MD more...
Medication Summary
Treatment of vasculitic neuropathy is based on the underlying cause of the vasculitis. Not all vasculitic neuropathies are treated with similar protocols.
Immunosuppressants
Class Summary
These agents are required for nearly all forms of vasculitic neuropathies; however, the choice of different types of immunosuppressants is based on the underlying cause. Similarly, adjust length of treatment and doses accordingly. In severe cases, IV methylprednisolone is recommended as "pulse" therapy.
Prednisone (Sterapred)
Immunosuppressant for treatment of autoimmune disorders. May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. Stabilizes lysosomal membranes and suppresses lymphocytes and antibody production.
Methylprednisolone (Medrol, Solu-Medrol, Depo-Medrol)
Decreases inflammation by suppressing migration of PMN leukocytes and reversing increased capillary permeability.
Cyclophosphamide (Cytoxan, Neosar)
Chemically related to nitrogen mustards. As alkylating agent, mechanism of action of active metabolites may involve cross-linking of DNA, which may interfere with growth of normal and neoplastic cells. In high doses, affects B cells by inhibiting clonal expansion and suppression of production of immunoglobulins. With long-term low-dose therapy, affects T cell functions.
Tricyclic antidepressants
Class Summary
Neuropathic pain frequently is seen with axonal degeneration and is secondary to inflammation or ischemia associated with vasculitis and nerve regeneration. Peripheral nerve regeneration is a slow process and may require months after the initial exacerbation or inflammation subsides. Patients may require long-term treatment for neuropathic pain. Use NSAIDs for acute or breakthrough pain; narcotics also are used and are a risk for addiction, especially with the chronicity of the symptoms. TCAs are used as first-line drugs in low doses for chronic or neuropathic pain.
Nortriptyline (Pamelor, Aventyl HCl)
Has demonstrated effectiveness in treatment of chronic pain. By inhibiting reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, increases synaptic concentration of these neurotransmitters in CNS. Pharmacodynamic effects such as desensitization of adenyl cyclase and down-regulation of beta-adrenergic receptors and serotonin receptors also appear to be involved in mechanisms of action. Patients developing sleep cycle disruption or insomnia can be switched to amitriptyline.
Amitriptyline (Elavil)
Analgesic for certain chronic and neuropathic pain. Patients developing daytime sedation can be switched to nortriptyline.
Anticonvulsants
Class Summary
Certain antiepileptic drugs have proven helpful in some cases of neuropathic pain.
Carbamazepine (Tegretol)
A sodium-channel blocker can provide significant relief of neuropathic pain. Adverse effect profile for older patients is more onerous than with newer anticonvulsants, thereby limiting usefulness in this group. Long-term use must be closely monitored and adjusted by treating physician.
Gabapentin (Neurontin)
Can be useful in treatment of neuropathic pain. Often tolerated better than carbamazepine by elderly patients. Can be used in patients with hepatic disease because undergoes renal clearance.
Nonsteroidal anti-inflammatory agents (NSAIDS)
Class Summary
These agents have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions.
Ibuprofen (Motrin, Ibuprin)
For patients with mild to moderately severe pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.
Kernohan JW, Woltman HW. Periarteritis nodosa: a clinicopathologic study with special reference to the nervous system. Arch Neurol Psychiatry. 1938;39:655-86.
Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain. Aug 1987;110 ( Pt 4):843-53. [Medline].
Davies L, Spies JM, Pollard JD, McLeod JG. Vasculitis confined to peripheral nerves. Brain. Oct 1996;119 ( Pt 5):1441-8. [Medline].
Kissel JT, Riethman JL, Omerza J, Rammohan KW, Mendell JR. Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann Neurol. Mar 1989;25(3):291-7. [Medline].
Murthy JM, Sundaram C, Meena AK. Nonsystemic vasculitic neuropathy. J Assoc Physicians India. Feb 1998;46(2):204-6. [Medline].
Larrode P, Ramon y Cajal S, Iníguez C, Dominguez M, Sanz JM, Morales F. [Isolated vasculitis of the peripheral nervous system]. Neurologia. May 1997;12(5):197-9. [Medline].
Collins MP, Mendell JR, Periquet MI, Sahenk Z, Amato AA, Gronseth GS. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology. Sep 12 2000;55(5):636-43. [Medline].
Sanchez GM, Villanueva-Haba VE, Sevilla Mantecon T, Mayordomo Fenandez F, Vilchez Padilla JJ. Nonsystemic vasculitic neuropathy. Neurologia. 2002;17:613-5.
Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. Sep 9 2003;61(5):623-30. [Medline].
Mathew L, Talbot K, Love S, Puvanarajah S, Donaghy M. Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. QJM. Jan 2007;100(1):41-51. [Medline].
Kissel JT, Slivka AP, Warmolts JR, Mendell JR. The clinical spectrum of necrotizing angiopathy of the peripheral nervous system. Ann Neurol. Aug 1985;18(2):251-7. [Medline].
Kararizou E, Davaki P, Karandreas N, Davou R, Vassilopoulos D. Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases. J Rheumatol. May 2005;32(5):853-8. [Medline].
Jayne D. Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford). Jun 2000;39(6):585-95. [Medline].
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. Feb 1994;37(2):187-92. [Medline].
Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. Jul 1967;43(1):8-14. [Medline].
Moore PM, Cupps TR. Neurological complications of vasculitis. Ann Neurol. Aug 1983;14(2):155-67. [Medline].
Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). Jan 1999;78(1):26-37. [Medline].
Sehgal M, Swanson JW, DeRemee RA, Colby TV. Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc. Apr 1995;70(4):337-41. [Medline].
Abgrall S, Mouthon L, Cohen P, et al. Localized neurological necrotizing vasculitides. Three cases with isolated mononeuritis multiplex. J Rheumatol. Mar 2001;28(3):631-3. [Medline].
Hawke SH, Davies L, Pamphlett R, et al. Vasculitic neuropathy. A clinical and pathological study. Brain. Oct 1991;114 ( Pt 5):2175-90. [Medline].
Johnson R, Griffin J. Current Therapy in Neurologic Disease. 5th ed. Philadelphia: BC Decker;. 1997.
Kissel JT, Mendell JR. Vasculitic neuropathy. Neurol Clin. Aug 1992;10(3):761-81. [Medline].
Olney RK. Neuropathies associated with connective tissue disease. Semin Neurol. 1998;18(1):63-72. [Medline].
Said G. Vasculitic neuropathy. Curr Opin Neurol. Oct 1999;12(5):627-9. [Medline].
Satoi H, Oka N, Kawasaki T, et al. Mechanisms of tissue injury in vasculitic neuropathies. Neurology. Feb 1998;50(2):492-6. [Medline].
Vedeler CA. Inflammatory neuropathies: update. Curr Opin Neurol. Jun 2000;13(3):305-9. [Medline].
Print
